EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prevalence and Description of Patients With Netherton Syndrome in France

Bodemer Christine, Droitcourt Catherine, Unigwe Ikenna, Najean Marie, Chollet Julien, Faujour Corentin, Bouée Stéphane, Jannot Anne‐Sophie

JEADV Clinical Practice · 18.11.2026

DOI: 10.1002/jvc2.70499 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JEADV Clinical Practice, online erschienen am 18.11.2026. Verfasst von Bodemer Christine und 7 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Boehringer Ingelheim.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Netherton syndrome (NS; recently designated SPINK5‐sEDD) is an autosomal recessive systemic epidermal differentiation disorder, which manifests at birth or shortly thereafter and is caused by loss‐of‐function mutations in the serine protease inhibitor of Kazal type 5 gene.

Objectives

The current study aims to provide data on the prevalence, demographics, mortality and clinical characteristics of individuals with NS in France.

Methods

This is a non‐interventional nationwide multicenter cross‐sectional study based on the ‘banque nationale de données maladies rares’ (BNDMR) database, that collects data for all patients attending rare disease referral centres. All patients diagnosed with NS who have received care at a referral centre in France were included in this study, unless they did not consent to their data being used for research purposes.

Results

On 1 January 2025, 111 patients were included in the database. Among the 111 patients, 64 (57.7%) were female, and 47 (42.3%) were male. The mean age by 1 January 2025 was 25.2 years. Of the 111 patients, nine were deceased by the time of data extraction. Based on the French population size at the same time point, a prevalence of 1.41 per million persons (95% CI: 1.15–1.73) is estimated. The majority of patients (88.0%) experienced their first symptoms within the first 28 days of life (newborn period). The mean delay between symptom onset and diagnosis was calculable for 63 patients (56.8%). Among them, 49.2% were diagnosed in the same month as symptom onset, 22.2% within the first year and 28.6% after more than 1 year.

Limitations

Patients with milder or undiagnosed disease, those who objected to the secondary use of their data for research and those who were never referred to an expert centre were not captured, potentially limiting the representativeness of the study population. In addition, missing data—particularly regarding diagnostic delay and neonatal characteristics—limited the completeness of some analyses.

Conclusions

This study leads to a prevalence of NS of 1.41 per million persons.

Förderung

  • Boehringer Ingelheim

Zitieren

APA

Christine, B., Catherine, D., Ikenna, U., Marie, N., Julien, C., Corentin, F., Stéphane, B., & Anne‐Sophie, J. (2026). Prevalence and Description of Patients With Netherton Syndrome in France. JEADV Clinical Practice. https://doi.org/10.1002/jvc2.70499

Vancouver

Christine B, Catherine D, Ikenna U, Marie N, Julien C, Corentin F, et al. Prevalence and Description of Patients With Netherton Syndrome in France. JEADV Clinical Practice. 2026. doi:10.1002/jvc2.70499

BibTeX
@article{Christine2026,
  author = {Christine, Bodemer and Catherine, Droitcourt and Ikenna, Unigwe and Marie, Najean and Julien, Chollet and Corentin, Faujour and Stéphane, Bouée and Anne‐Sophie, Jannot},
  title = {Prevalence and Description of Patients With Netherton Syndrome in France},
  journal = {JEADV Clinical Practice},
  year = {2026},
  doi = {10.1002/jvc2.70499}
}
Kostenlos starten →